Pacific Edge Lifts Test Volumes 2.7% as Medicare Coverage Decision Looms in 2027
Volume growth signals underlying demand as Medicare pathway clears
Pacific Edge (ASX: PEB) reported laboratory throughput of 5,582 tests in Q4 26, representing a 2.7% increase on the prior quarter, as Pacific Edge Medicare coverage momentum builds following a pivotal February meeting that positions the diagnostics company for a potential reimbursement catalyst within 12 months. The quarterly report, covering the three months to 31 March 2026, revealed sustained volume growth despite capital preservation measures that saw the US sales force reduced by 36% to 7.7 FTE.
US laboratory throughput rose 1.0% to 4,064 tests, primarily reflecting Kaiser Permanente Southern California volume expansion. Asia-Pacific volumes climbed 7.7% to 1,518 tests, driven by commercial test growth and increased clinical study activity. The volume gains occurred against a backdrop of product transition disruption (migrating customers from Cxbladder Detect to Triage), Medicare non-coverage headwinds, and weather-related operational disruptions from winter storms across US facilities.
Sales force efficiency metrics improved materially, with tests per sales FTE rising to 530 from 335 in Q3 26. Tests per ordering clinician increased to 5.4 from 4.8, although total ordering clinicians declined to 747 from 834 as the reduced sales footprint limited new clinician acquisition. Management attributed the efficiency gains to its policy of limiting backfilling in not-yet-profitable territories ahead of Medicare reimbursement certainty.
Dr Peter Meintjes, Chief Executive
“Pacific Edge enters the new financial year on the cusp of a major commercial inflection point. Backed by robust clinical evidence, the endorsement of our tests in clinical guidelines, and growing momentum in clinical opinion, we have firmly established ourselves as the first mover and market leader in bladder cancer diagnostics.”
When big ASX news breaks, our subscribers know first
Understanding local coverage determinations in Medicare policy
A local coverage determination (LCD) is Medicare’s regional policy framework that establishes whether a diagnostic test qualifies for reimbursement within a specific geographic jurisdiction. For Pacific Edge, the relevant authority is Novitas, the Medicare Administrative Contractor with jurisdiction over the company’s Pennsylvania laboratory operations.
The LCD development process typically begins with a Contractor Advisory Committee (CAC) meeting, where an expert panel reviews clinical evidence and provides guidance to the MAC. On 19 February 2026, Novitas convened a CAC focused on urine-based biomarkers for hematuria evaluation. The expert panel delivered strong support for Cxbladder, highlighting unmet clinical needs across microhematuria and gross hematuria risk categories, potential to deliver healthcare equity for rural and underserved patient groups, and the clinical evidence supporting guideline inclusion.
Following the CAC, Novitas published a meeting transcript in March, a procedural requirement before draft LCD policy can be released. Pacific Edge maintains its expectation for a draft LCD before the end of September 2026, with final effective coverage estimated approximately six months thereafter. Once published, the draft undergoes a public comment period before Novitas finalizes coverage terms.
Medicare coverage removes the primary barrier to US commercial adoption. It unlocks predictable revenue recognition, typically catalyses commercial payer policy alignment, and establishes independent clinical validation that influences physician behaviour and institutional procurement decisions.
Commercial payer wins validate clinical evidence ahead of Medicare decision
Pacific Edge secured three material commercial payer coverage decisions in Q4 26, expanding reimbursed access by 11.2 million covered lives. Blue Cross Blue Shield North Carolina (~3.4 million lives) and Blue Cross Blue Shield South Carolina (~762,000 lives) adopted medical policy for Cxbladder Triage in March 2026. Both policies mirror coverage language established by Avalon Healthcare Systems in February, demonstrating the influence third-party evidence review organisations exert on commercial payer decisions.
Separately, Highmark, an independent Blue Cross Blue Shield licensee covering 7 million lives, adopted medical policy for Cxbladder Monitor for bladder cancer surveillance. The combined payer access expansion exceeds twice the patient population Pacific Edge reaches through Kaiser Permanente Southern California.
| Payer | Product Covered | Covered Lives | Policy Timing |
|---|---|---|---|
| BCBS North Carolina | Triage | ~3.4m | March 2026 |
| BCBS South Carolina | Triage | ~762k | March 2026 |
| Highmark | Monitor | 7m | Q4 26 |
The policy wins validate Pacific Edge’s commercial payer strategy of establishing medical policy through direct engagement with large payers, major lab benefit management organisations, and relevant data curators. With approximately 1,200 US commercial payers collectively covering over 223 million Americans, medical policy adoption among major BCBS plans provides a replicable template for broader payer network expansion.
Commercial payer coverage typically commands premium pricing relative to Medicare rates, supporting average sales price growth as the company transitions from out-of-network to in-network reimbursement. The adoption also provides proof of concept that Pacific Edge’s clinical evidence portfolio, anchored by the STRATA randomised controlled trial and American Urological Association guideline inclusion, is sufficient to support reimbursement without Medicare precedent.
Asia-Pacific clinical pathway milestones establish regional footprint
Pacific Edge achieved its first Southeast Asian clinical pathway implementation at Singapore General Hospital (SGH), the largest and oldest hospital in Singapore serving more than one million patients annually. SGH, a publicly funded institution operating under capitated healthcare economics, has incorporated Cxbladder Triage, Triage Plus, and Monitor into patient care pathways. Eligible patients will be offered a choice between cystoscopy and Cxbladder, acknowledging the test’s clinical and economic value proposition.
As a leading tertiary hospital, SGH’s adoption is positioned to influence clinical practice standards across the Asia-Pacific region. The implementation marks the first clinical use of Triage Plus in any clinical pathway globally, demonstrating institutional confidence in the product’s performance characteristics ahead of peer-reviewed publication.
In Australia, Townsville University Hospital has begun clinical use of Cxbladder Triage Plus and Monitor. The hospital serves a local population of 250,000 and a referral catchment of 700,000 across North Queensland. The implementation covers hematuria evaluation and non-muscle invasive bladder cancer surveillance. Notably, consultant urologists at Townsville have established a nurse-led ordering protocol, highlighting operational efficiency advantages inherent to genomic urine testing versus invasive cystoscopy workflows.
Operating leverage emerges as sales efficiency metrics climb
Pacific Edge’s capital preservation strategy reduced the US sales force from 12.0 FTE to 7.7 FTE during Q4 26, a 36% contraction designed to preserve cash runway ahead of Medicare reimbursement certainty. Despite the reduced headcount, laboratory throughput increased sequentially, demonstrating underlying demand resilience and validating management’s thesis that Medicare non-coverage, rather than clinical acceptance, remains the binding constraint on adoption.
Key efficiency metrics improved materially quarter-on-quarter:
- Tests per sales FTE: 530 (up from 335 in Q3 26)
- Tests per ordering clinician: 5.4 (up from 4.8)
- Ordering clinicians: 747 (down from 834)
- Sales FTE: 7.7 (down from 12.0)
The efficiency gains reflect management’s policy of limiting backfilling in territories not yet profitable under Medicare non-coverage. The tests-per-clinician metric indicates deepening engagement among existing accounts, while the absolute decline in ordering clinicians reflects the natural attrition expected when sales coverage contracts. The company is positioned to scale rapidly once Medicare reimbursement removes adoption friction, with the reduced cost base supporting improved unit economics as volumes ramp.
The next major ASX story will hit our subscribers first
Investment thesis converges on regulatory, commercial, and clinical catalysts
Pacific Edge enters FY27 with regulatory, commercial, and clinical momentum converging toward a potential inflection point. The February CAC outcome, underpinned by strong expert panel support for urine-based biomarkers, positions the company for draft LCD publication before the end of September 2026. Final effective Medicare coverage is anticipated approximately six months following draft publication, placing potential reimbursement in early-to-mid 2027.
The commercial payer wins at BCBS North Carolina, BCBS South Carolina, and Highmark demonstrate that Pacific Edge’s clinical evidence portfolio, anchored by over 25 peer-reviewed publications and more than 130,000 tests ordered by over 5,000 urologists, is sufficient to support reimbursement independent of Medicare precedent. The AUSSIE study, which received the Best Oncology Presentation award at USANZ 2026, is targeting peer-reviewed publication by September 2026, adding to the evidence base supporting Triage Plus performance characteristics.
Pacific Edge filed a Patent Cooperation Treaty application for Triage Plus in March 2026, highlighting the novel inventive step in combining DNA SNVs with existing mRNA biomarkers through novel algorithmic analysis. The PCT filing preserves the priority date established by a provisional application in March 2025 and provides a streamlined pathway to pursue jurisdiction-specific patent protection aligned with commercial strategy.
The company expects to release FY26 financial results toward the end of May 2026.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors getting FREE breaking ASX healthcare news delivered within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to receive real-time alerts on market-moving announcements the moment they hit the ASX.